

Bernd JahrsdÄrfer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9852397/publications.pdf>

Version: 2024-02-01

23
papers

1,972
citations

623734

14
h-index

713466

21
g-index

29
all docs

29
docs citations

29
times ranked

4550
citing authors

#	ARTICLE	IF	CITATIONS
1	Erytra blood group analyser and kode technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals. <i>EJHaem</i> , 2022, 3, 72-79.	1.0	4
2	Robust and durable serological response following pediatric SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 128.	12.8	54
3	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. <i>EBioMedicine</i> , 2022, 75, 103761.	6.1	104
4	B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. <i>Arthritis and Rheumatology</i> , 2022, 74, 934-947.	5.6	55
5	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. <i>JCI Insight</i> , 2022, 7, .	5.0	62
6	B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients. <i>Frontiers in Immunology</i> , 2022, 13, 822885.	4.8	7
7	Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing. <i>Journal of Infectious Diseases</i> , 2021, 223, 796-801.	4.0	51
8	SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. <i>Cell</i> , 2021, 184, 2384-2393.e12.	28.9	848
9	Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19 Convalescent Donors. <i>Journal of Immunology</i> , 2021, 206, 2614-2622.	0.8	22
10	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021, 6, eabj1031.	11.9	223
11	Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	212
12	mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. <i>Vaccines</i> , 2021, 9, 918.	4.4	40
13	BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. <i>Frontiers in Immunology</i> , 2021, 12, 743422.	4.8	10
14	Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies. <i>Transfusion Medicine and Hemotherapy</i> , 2021, 48, 137-147.	1.6	21
15	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3027-3033.	6.1	82
16	An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection. <i>Antiviral Research</i> , 2020, 181, 104882.	4.1	34
17	ATP promotes immunosuppressive capacities of mesenchymal stromal cells by enhancing the expression of indoleamine dioxygenase. <i>Immunity, Inflammation and Disease</i> , 2018, 6, 448-455.	2.7	11
18	Differential expression of serpins may selectively licence distinct granzyme B functions including antigen cross-presentation. <i>Molecular Immunology</i> , 2017, 87, 325-326.	2.2	1

#	ARTICLE	IF	CITATIONS
19	Hepcidin/Ferritin Quotient Helps to Predict Spontaneous Recovery from Iron Loss following Blood Donation. <i>Transfusion Medicine and Hemotherapy</i> , 2015, 42, 390-395.	1.6	7
20	CD4+ T Cellâ€‘Derived IL-21 and Deprivation of CD40 Signaling Favor the In Vivo Development of Granzyme Bâ€‘Expressing Regulatory B Cells in HIV Patients. <i>Journal of Immunology</i> , 2015, 194, 3768-3777.	0.8	57
21	S100A4 and Uric Acid Promote Mesenchymal Stromal Cell Induction of IL-10+/IDO+ Lymphocytes. <i>Journal of Immunology</i> , 2014, 192, 6102-6110.	0.8	35
22	CD27+IgDâ€‘ B cells in the peripheral blood of colorectal cancer patients: on anti-tumor or tumor-protective mission?. <i>Oncoscience</i> , 2014, 1, 558-559.	2.2	0
23	BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4